Broad- and narrow-sense validity performance of three polygenic risk score methods for prostate cancer risk assessment

被引:7
|
作者
Yu, Hongjie [1 ]
Shi, Zhuqing [1 ]
Lin, Xiaoling [2 ]
Bao, Quanwa [3 ]
Jia, Haifei [2 ]
Wei, Jun [1 ]
Helfand, Brian T. [1 ]
Zheng, Siqun. L. [1 ]
Duggan, David [4 ]
Lu, Daru [3 ]
Mo, Zengnan [5 ]
Xu, Jianfeng [1 ,2 ]
机构
[1] NorthShore Univ HealthSyst, Program Personalized Canc Care, 1001 Univ Pl, Evanston, IL 60201 USA
[2] Fudan Univ, Huashan Hosp, Fudan Inst Urol, Shanghai, Peoples R China
[3] Fudan Univ, Sch Life Sci, State Key Lab Genet Engn, Shanghai, Peoples R China
[4] City Hope Natl Med Ctr, Translat Genom Res Inst, Phoenix, AZ USA
[5] Guangxi Med Univ, Ctr Genom & Personalized Med, Nanning, Guangxi Zhuang, Peoples R China
来源
PROSTATE | 2020年 / 80卷 / 01期
关键词
clinical validity; genetic risk score; prostate cancer; GENOME-WIDE ASSOCIATION; MEN; PREDICTION; VARIANTS; BIOPSY;
D O I
10.1002/pros.23920
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Several polygenic risk score (PRS) methods are available for measuring the cumulative effect of multiple risk-associated single nucleotide polymorphisms (SNPs). Their performance in predicting risk at the individual level has not been well studied. Methods We compared the performance of three PRS methods for prostate cancer risk assessment in a clinical trial cohort, including genetic risk score (GRS), pruning and thresholding (P + T), and linkage disequilibrium prediction (LDpred). Performance was evaluated for score deciles (broad-sense validity) and score values (narrow-sense validity). Results A training process was required to identify the best P + T model (397 SNPs) and LDpred model (3 011 362 SNPs). In contrast, GRS was directly calculated based on 110 established risk-associated SNPs. For broad-sense validity in the testing population, higher deciles were significantly associated with higher observed risk;P(trend)was 7.40 x 10(-11), 7.64 x 10(-13), and 7.51 x 10(-10)for GRS, P + T, and LDpred, respectively. For narrow-sense validity, the calibration slope (1 is best) was 1.03, 0.77, and 0.87, and mean bias score (0 is best) was 0.09, 0.21, and 0.10 for GRS, P + T, and LDpred, respectively. Conclusions The performance of GRS was better than P + T and LDpred. Fewer and well-established SNPs of GRS also make it more feasible and interpretable for genetic testing at the individual level.
引用
收藏
页码:83 / 87
页数:5
相关论文
共 50 条
  • [31] Cross-ancestry polygenic risk score for breast cancer risk assessment.
    Tshiaba, Placede
    Sun, Jiayi
    Ratman, Dariusz
    Tunstall, Tate
    Levy, Brynn
    Shah, Premal
    Rabinowitz, Matthew
    Kumar, Akash
    Im, Kate
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [32] Polygenic risk score strategies for transcriptome-wide association analysis in prostate cancer risk
    Larson, Nicholas B.
    McDonnell, Shannon K.
    Fogarty, Zachary
    EUROPEAN JOURNAL OF HUMAN GENETICS, 2022, 30 (SUPPL 1) : 498 - 498
  • [33] Polygenic risk score for genetic evaluation of prostate cancer risk in Asian populations: A narrative review
    Song, Sang Hun
    Byun, Seok-Soo
    INVESTIGATIVE AND CLINICAL UROLOGY, 2021, 62 (03) : 256 - 266
  • [34] Polygenic Risk Score Modifies Prostate Cancer Risk of Pathogenic Variants in Men of African Ancestry
    Hughley, Raymond W.
    Matejcic, Marco
    Song, Ziwei
    Sheng, Xin
    Wan, Peggy
    Xia, Lucy
    Hart, Steven N.
    Hu, Chunling
    Yadav, Siddhartha
    Lubmawa, Alexander
    Kiddu, Vicky
    Asiimwe, Frank
    Amanya, Colline
    Mutema, George
    Job, Kuteesa
    Ssebakumba, Mbaaga K.
    Ingles, Sue A.
    Hamilton, Ann S.
    Couch, Fergus J.
    Watya, Stephen
    Conti, David V.
    Darst, Burcu F.
    Haiman, Christopher A.
    CANCER RESEARCH COMMUNICATIONS, 2023, 3 (12): : 2544 - 2550
  • [35] Polygenic Risk Score and Upgrading in Patients With Prostate Cancer Receiving Active Surveillance
    Goss, Louisa B.
    Liu, Menghan
    Zheng, Yingye
    Guo, Boya
    Conti, David V.
    Haiman, Christopher A.
    Kachuri, Linda
    Catalona, William J.
    Witte, John S.
    Lin, Daniel W.
    Newcomb, Lisa F.
    Darst, Burcu F.
    JAMA ONCOLOGY, 2025, 11 (02) : 168 - 171
  • [36] Additional SNPs improve risk stratification of a polygenic hazard score for prostate cancer
    Karunamuni, Roshan A.
    Huynh-Le, Minh-Phuong
    Fan, Chun C.
    Thompson, Wesley
    Eeles, Rosalind A.
    Kote-Jarai, Zsofia
    Muir, Kenneth
    Lophatananon, Artitaya
    Schleutker, Johanna
    Pashayan, Nora
    Batra, Jyotsna
    Groenberg, Henrik
    Walsh, Eleanor I.
    Turner, Emma L.
    Lane, Athene
    Martin, Richard M.
    Neal, David E.
    Donovan, Jenny L.
    Hamdy, Freddie C.
    Nordestgaard, Borge G.
    Tangen, Catherine M.
    MacInnis, Robert J.
    Wolk, Alicja
    Albanes, Demetrius
    Haiman, Christopher A.
    Travis, Ruth C.
    Stanford, Janet L.
    Mucci, Lorelei A.
    West, Catharine M. L.
    Nielsen, Sune F.
    Kibel, Adam S.
    Wiklund, Fredrik
    Cussenot, Olivier
    Berndt, Sonja I.
    Koutros, Stella
    Sorensen, Karina Dalsgaard
    Cybulski, Cezary
    Grindedal, Eli Marie
    Park, Jong Y.
    Ingles, Sue A.
    Maier, Christiane
    Hamilton, Robert J.
    Rosenstein, Barry S.
    Vega, Ana
    Kogevinas, Manolis
    Penney, Kathryn L.
    Teixeira, Manuel R.
    Brenner, Hermann
    John, Esther M.
    Kaneva, Radka
    PROSTATE CANCER AND PROSTATIC DISEASES, 2021, 24 (02) : 532 - 541
  • [37] Additional SNPs improve risk stratification of a polygenic hazard score for prostate cancer
    Roshan A. Karunamuni
    Minh-Phuong Huynh-Le
    Chun C. Fan
    Wesley Thompson
    Rosalind A. Eeles
    Zsofia Kote-Jarai
    Kenneth Muir
    Artitaya Lophatananon
    Johanna Schleutker
    Nora Pashayan
    Jyotsna Batra
    Henrik Grönberg
    Eleanor I. Walsh
    Emma L. Turner
    Athene Lane
    Richard M. Martin
    David E. Neal
    Jenny L. Donovan
    Freddie C. Hamdy
    Børge G. Nordestgaard
    Catherine M. Tangen
    Robert J. MacInnis
    Alicja Wolk
    Demetrius Albanes
    Christopher A. Haiman
    Ruth C. Travis
    Janet L. Stanford
    Lorelei A. Mucci
    Catharine M. L. West
    Sune F. Nielsen
    Adam S. Kibel
    Fredrik Wiklund
    Olivier Cussenot
    Sonja I. Berndt
    Stella Koutros
    Karina Dalsgaard Sørensen
    Cezary Cybulski
    Eli Marie Grindedal
    Jong Y. Park
    Sue A. Ingles
    Christiane Maier
    Robert J. Hamilton
    Barry S. Rosenstein
    Ana Vega
    Manolis Kogevinas
    Kathryn L. Penney
    Manuel R. Teixeira
    Hermann Brenner
    Esther M. John
    Radka Kaneva
    Prostate Cancer and Prostatic Diseases, 2021, 24 : 532 - 541
  • [38] Performance of breast cancer polygenic risk score (PRS) in a Ghanaian population
    Ahearn, Thomas U.
    Derkach, Andriy
    Yarney, Joel
    Addai, Beatrice Wiafe
    Awuah, Baffour
    Brinton, Louise
    Chatterjee, Nilanjan
    Figueroa, Jonine D.
    Garcia-Closas, Montserrat
    CANCER RESEARCH, 2019, 79 (13)
  • [39] Integration of Polygenic Risk Score (PRS) with multiparametric MRI in men at risk for clinically significant prostate cancer
    Plym, A.
    Madueke, I. C.
    Naik, S.
    Penney, K. L.
    Mucci, L. A.
    Khorasani, R.
    Kibel, A. S.
    EUROPEAN UROLOGY, 2023, 83 : S104 - S105
  • [40] GENETIC RISK ASSESSMENT OF LETHAL PROSTATE CANCER USING BENIGN PROSTATIC HYPERPLASIA OR PROSTATE VOLUME-RELATED POLYGENIC RISK SCORE AND HEREDITARY CANCER SUSCEPTIBILITY GENES
    Ruan, Xiaohao
    Huang, Da
    Huang, Jingyi
    Xu, Danfeng
    Tsu, James
    Na, Rong
    JOURNAL OF UROLOGY, 2023, 209 : E616 - E617